Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro

21 Jan 2022

Abstract excerpt

Abstract Background Alzheimer’s disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau protein that forms fibrillar deposits in the brain. In AD, Tau pathology correlates strongly with clinical symptoms, cognitive dysfunction, and neuronal death. Methods We aimed to develop...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amino Acid Enzymes and Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35063014
DOI: 10.1186/s13195-022-00959-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitroPMID 35063014Read ↗

Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer’s disease and other TauopathiesSemantic proximity Read ↗

Direct disassembly of α-syn preformed fibrils into native α-syn monomers by an all-D-peptideSemantic proximity Read ↗

Single Domain Antibody Fragments as New Tools for the Detection of Neuronal Tau Protein in Cells and in Mice StudiesSemantic proximity Read ↗

Inhibition of tau neuronal internalization using anti-tau single domain antibodiesSemantic proximity Read ↗

A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathiesSemantic proximity Read ↗

Highly Potent Peptide Therapeutics To Prevent Protein Aggregation In Huntington’s DiseaseSemantic proximity Read ↗

AI-Guided Dual Strategy for Peptide Inhibitor Design Targeting Structural Polymorphs of α-Synuclein FibrilsSemantic proximity Read ↗

AI-guided design and <i>ex vivo</i> validation of nanobodies targeting aggregation motifs of intrinsically disordered protein tauSemantic proximity Read ↗

Phage display derived peptides for Alzheimer's disease therapy and diagnosisSemantic proximity Read ↗

Reduction of Alzheimer’s Disease Amyloid Plaque Load in Transgenic Mice by D3, a <scp>D</scp> ‐Enantiomeric Peptide Identified by Mirror Image Phage DisplaySemantic proximity Read ↗

Anti-tau single domain antibodies clear pathological tau and attenuate its toxicity and related functional defectsSemantic proximity Read ↗

Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.